E
BioAge Labs, Inc. BIOA
$4.34 $0.112.60% NASDAQ
Recommendation
Prev Close
$4.23
Volume
246,627
Avg Vol (90D)
430,174
Market Cap
$151.65M
Dividend & Yield
--
52-Week Range
$2.88 - $26.62
P/E (TTM)
--
EPS (TTM)
-$22.99
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Notice to Long-Term Shareholders of BioAge Labs, Inc. (NASDAQ: BIOA); Driven Bands Holdings, Inc. (NASDAQ: DRVN); Integra LifeSciences Holdings Corporation (NASDAQ: IART); and Monolithic Power Systems, Inc. (NASDAQ: MPWR): Grabar Law Office Investigates Claims on Your Behalf
4/24/2025 - Globe Newswire
Notice to Long-Term Shareholders of BioAge Labs, Inc. (NASDAQ: BIOA); Driven Bands Holdings, Inc. (NASDAQ: DRVN); Integra Lifesciences Holdings Corporation (NASDAQ: IART); and Monolithic Power Systems, Inc. (NASDAQ: MPWR): Grabar Law Office Investigates Claims on Your Behalf
4/22/2025 - Globe Newswire
BioAge Labs, Inc. (BIOA): A Bull Case Theory
4/21/2025 - Yahoo! Finance: News
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of BioAge Labs, Inc. (NASDAQ: BIOA); NAPCO Security Technologies, Inc. (NASDAQ: NSSC); Treace Medical Concepts, Inc. (NASDAQ: TMCI); and Virtu Financial Inc. (NASDAQ: VIRT)
4/17/2025 - Globe Newswire
Look Under The Hood: FESM Has 30% Upside
3/26/2025 - ETF Channel
BioAge Labs price target lowered to $5 from $7 at Citi
3/23/2025 - TipRanks Financial Blog
BioAge Labs price target lowered by $2 at Citi, here's why
3/23/2025 - The Fly
BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the ...
3/20/2025 - GuruFocus
BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024
3/20/2025 - Globe Newswire
BioArctic receives Orphan Drug Designation for exidavnemab the US
3/17/2025 - PR Newswire
Final Deadline for the BioAge Labs, Inc. Securities Lawsuit - Contact the DJS Law Group to ...
3/11/2025 - GuruFocus
Final Deadline for the BioAge Labs, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - BIOA
3/11/2025 - PR Newswire
BIOA Deadline Today: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit
3/10/2025 - GuruFocus
BIOA Deadline Today: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit
3/10/2025 - PR Newswire
BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. ...
3/10/2025 - GuruFocus
BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Fraud Lawsuit with the Schall Law Firm
3/10/2025 - Business Wire
Lost Money on BioAge Labs, Inc. (BIOA)? Join Class Action Suit Seeking Recovery -- Contact Levi ...
3/10/2025 - GuruFocus
BIOA FINAL DEADLINE: BioAge Labs Investors are Encouraged to Contact BFA Law before the ...
3/10/2025 - GuruFocus
BioAge Labs, Inc. Class Action: The Gross Law Firm Reminds BioAge Investors of the Pending ...
3/10/2025 - GuruFocus
BioAge Labs, Inc. Class Action: The Gross Law Firm Reminds BioAge Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - BIOA
3/10/2025 - PR Newswire
BIOA Final Opportunity to Lead BioAge Labs, Inc. Securities Fraud Lawsuit with the Schall Law Firm
3/10/2025 - GuruFocus
BIOA Final Opportunity to Lead BioAge Labs, Inc. Securities Fraud Lawsuit with the Schall Law Firm
3/10/2025 - PR Newswire
BIOA LEGAL NEWS: A Class Action was filed on behalf of BioAge Labs Investors - Contact BFA Law ...
3/8/2025 - GuruFocus
BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit -- Hagens Berman
3/7/2025 - GuruFocus
BIOA Deadline in 3 Days: Kessler Topaz Meltzer & Check, LLP Reminds BioAge Labs, Inc. ...
3/7/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$78.03M
EBIT (TTM)
-$78.19M
Net Income (TTM)
-$71.11M
Balance Sheet
Total Assets (Q)
$358.23M
Total Debt (Q)
$8.70M
Total Liabilities (Q)
$35.11M
Book Value Per Share (Q)
$9.01
Cash Flow
Cash from Operations (TTM)
-$51.52M
Cash from Investing (TTM)
-$366.00K
Cash from Financing (TTM)
$381.20M
Net Change in Cash (TTM)
$329.39M
Filings
Filing Date
Thursday, March 20, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 26 and 30 (est)
Price History
Loading...
Beta
--
7-Day Total Return
15.73%
30-Day Total Return
-0.23%
60-Day Total Return
-9.21%
90-Day Total Return
1.40%
Year to Date Total Return
-21.94%
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Apr 09, 2025 - $2.88
52-week High
Oct 22, 2024 - $26.62
Valuation
Market Cap
$151.65M - Micro Cap
Enterprise Value
-$194.00M
Price/Sales (TTM)
--
Price/Book (Q)
0.47
Dividends and Shares
Shares Outstanding
36.01M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
bioagelabs.com
Phone Number
510 806 1445
Address
1445A South 50th Street
Richmond, CA 94804
Country
United States
Year Founded
2015
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
BioAge Labs, Inc. is a biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets allows... more
NASDAQ 04/28/2025 3:15PM Eastern Quotes delayed